2696 Recruiting Trials

Clinical Trials in North Carolina

Browse 2696 recruiting clinical trials currently enrolling participants in North Carolina. Search by condition to find trials you may qualify for — at no cost.

Showing 15 of 2696 recruiting trials in North Carolina

Immune Cell Response to Stimuli
N/A Research Triangle Park, North Carolina · Inflammation
Recruiting
Study of the Effect of Innate on the Inflammatory Response to Endotoxin
N/A Research Triangle Park, North Carolina · Asthma, Cancer
Recruiting
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
PHASE2 Anchorage, Alaska +4 sites · Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma
Recruiting
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
PHASE2 Birmingham, Alabama +4 sites · Sarcomatoid Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
Recruiting
Real-world Experience of Catheter Ablation for the Treatment of Arrhythmias
N/A Birmingham, Alabama +4 sites · Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation
Recruiting
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
PHASE3 Birmingham, Alabama +4 sites · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Recruiting
Hydrus® Microstent New Enrollment Post-Approval Study
NA Irvine, California +4 sites · Primary Open Angle Glaucoma
Recruiting
Recruiting
Neural Correlates of Real World Spatial Navigation in Humans
NA Los Angeles, California +1 sites · Memory, Delayed
Recruiting
Natural History of the Human Biological Response to Environmental Exposure and Injury
N/A Research Triangle Park, North Carolina · Inflammation, Metabolic Disease
Recruiting
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
PHASE2 Birmingham, Alabama +4 sites · Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma
Recruiting